DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/7k38js/uterine_cancer) has announced the addition of the "Uterine cancer Pipeline Highlights - 2014 Update" report to their offering.
The latest report Uterine cancer Pipeline Highlights - 2014 Update, provides most up-to-date information on key pipeline molecules in the global Uterine cancer market. It covers emerging therapies for Uterine cancer in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Uterine cancer pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Uterine cancer pipeline molecules by their dominant mechanism of action. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides Uterine cancer pipeline molecules by the Originator Company.
Short-term Launch Highlights:
Find out which Uterine cancer pipeline products will be launched in the US and Ex-US till 2017.
- Uterine cancer phase 3 clinical trial pipeline molecules
- Uterine cancer phase 2 clinical trial pipeline molecules
- Uterine cancer phase 1 clinical trial pipeline molecules
- Uterine cancer preclinical research pipeline molecules
- Uterine cancer discovery stage pipeline molecules
- Uterine cancer pipeline molecules short-term launch highlights
For more information visit http://www.researchandmarkets.com/research/7k38js/uterine_cancer